InterVenn BioSciences Corp (InterVenn) is a biotechnology company that focuses on advancing personalized medicine by decoding the human glycoproteome. InterVenn’s lead product GlycoVision, is an artificial intelligence and machine learning biomarker discovery platform that provides a high-resolution view into an untapped layer of biology. The company collaborates with pharmaceutical, biotechnology, and diagnostic companies to accelerate disease insights and improve drug development. InterVenn BioSciences is headquartered in South San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company InterVenn BioSciences
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
InterVenn BioSciences Company Overview
InterVenn BioSciences Company Snapshot
InterVenn BioSciences Pipeline Products and Ongoing Clinical Trials Overview
InterVenn BioSciences - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
InterVenn BioSciences, Recent Developments
Oct 13, 2023: InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
Sep 27, 2023: InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
Apr 19, 2023: InterVenn Biosciences to present clinical data on circulating serum glycoproteins for unprecedented pre-cancer detection as “poster of distinction” at Digestive Disease Week 2023
Oct 26, 2022: Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
Oct 04, 2022: InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth
Sep 09, 2022: InterVenn Biosciences to Present at the 20th Annual Morgan Stanley Global Healthcare Conference
Sep 06, 2022: InterVenn Biosciences to present at the 20th Annual Morgan Stanley Global Healthcare Conference
Jun 02, 2022: Intervenn Biosciences announces new data validating the clinical performance of DAWN IO Melanoma as a novel liquid biopsy test to improve assessment of benefit to cancer patients
Jun 01, 2022: InterVenn Biosciences joins the WIN and FNIH Biomarker Consortiums to introduce a Glycoproteomic Option for Liquid Biopsies
May 06, 2022: InterVenn to present new clinical data at ASCO 2022 on using Glycoproteomics as powerful liquid biopsy tests for early detection of cancer and prediction of checkpoint inhibitor treatment benefit
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
InterVenn BioSciences Pipeline Products and Ongoing Clinical Trials Overview
InterVenn BioSciences Pipeline Products by Equipment Type
InterVenn BioSciences Pipeline Products by Indication
InterVenn BioSciences, Key Facts
InterVenn BioSciences, Major Products and Services
InterVenn BioSciences Number of Pipeline Products by Development Stage
InterVenn BioSciences Pipeline Products Summary by Development Stage
Blood-Based Diagnostic Test - Advanced Adenoma - Product Status
Blood-Based Diagnostic Test - Advanced Adenoma - Product Description
Blood-Based Diagnostic Test - Hepatocellular Carcinoma - Product Status
Blood-Based Diagnostic Test - Hepatocellular Carcinoma - Product Description
Blood-Based Diagnostic Test - Nasopharyngeal Carcinoma - Product Status
Blood-Based Diagnostic Test - Nasopharyngeal Carcinoma - Product Description
Blood-Based Diagnostic Test - Non-Alcoholic SteatoHepatitis - Product Status
Blood-Based Diagnostic Test - Non-Alcoholic SteatoHepatitis - Product Description
Blood-Based Diagnostic Test - Non-Small Cell Lung Cancer - Product Status
Blood-Based Diagnostic Test - Non-Small Cell Lung Cancer - Product Description
Blood-Based Diagnostic Test - Pancreatic Cancer - Product Status
Blood-Based Diagnostic Test - Pancreatic Cancer - Product Description
Blood-Based Diagnostic Test - Prostate Cancer - Product Status
Blood-Based Diagnostic Test - Prostate Cancer - Product Description
Blood-Based Diagnostic Test - Renal Cell Carcinoma - Product Status
Blood-Based Diagnostic Test - Renal Cell Carcinoma - Product Description
Dawn - Lung Cancer - Product Status
Dawn - Lung Cancer - Product Description
Dawn - Pancreatic Cancer - Product Status
Dawn - Pancreatic Cancer - Product Description
Dawn IO Melanoma - Product Status
Dawn IO Melanoma - Product Description
Diagnostic Test - Bone Cancer - Product Status
Diagnostic Test - Bone Cancer - Product Description
Diagnostic Test - Soft Tissue Sarcoma - Product Status
Diagnostic Test - Soft Tissue Sarcoma - Product Description
Glori - Product Status
Glori - Product Description
GlycoKnow Colon - Product Status
GlycoKnow Colon - Product Description
Immuno-Therapy Response Prediction Test - NSCLC - Product Status
Immuno-Therapy Response Prediction Test - NSCLC - Product Description
Treatment Monitoring Panel - Autoimmune Diseases - Product Status